Home › Funds › Birchview Capital, LP › RARE

Birchview Capital, LP position in RARE

ULTRAGENYX PHARMACEUTICAL IN · Health Care

Birchview Capital, LP reported holding 373,671 shares of RARE (ULTRAGENYX PHARMACEUTICAL IN) in its Q3 2026 13F filing — a position valued at US$5.6M, representing 3.34% of its reported portfolio and ranking #7 among its reported holdings. Birchview Capital, LP has disclosed RARE holdings in 7 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)373.67K sh
Reported value held$5.62M
Portfolio Weight3.34%
First reportedQ4 2024
Last changeNew
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Birchview Capital, LP's RARE position evolved

Birchview Capital, LP first disclosed a stake in RARE in Q4 2024 at 16,000 shares (US$673K). The position peaked in Q3 2026 at 373,671 shares, worth US$5.6M. Across 7 filings, Birchview Capital, LP increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 373,671 shares valued at US$5.6M. Notable position changes include a 182% increase in Q4 2025 (shares fell 9% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 16.00K $673.12K New
Q1 2025 16.00K $579.36K Hold
Q2 2025 18.00K $654.48K Add
Q3 2025 22.00K $661.76K Add
Q4 2025 62.00K $1.43M Add
Q1 2026 62.00K $1.30M Hold
Q3 2026 373.67K $5.62M New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RARE and 13F data

RARE (ULTRAGENYX PHARMACEUTICAL IN) is a Health Care company. 24 other funds we track also report a position in RARE — the largest reported positions include RTW INVESTMENTS, LP (US$260.3M), FRONTIER CAPITAL MANAGEMENT CO LLC (US$95.1M), Bellevue Group AG (US$66.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RARE

All RARE fund holders →

FAQ

How long has Birchview Capital, LP held RARE?

Birchview Capital, LP has disclosed RARE holdings in 7 of the last 8 reported quarters, going back to Q4 2024.

What is Birchview Capital, LP's current position in RARE?

As of Q3 2026, Birchview Capital, LP holds 373.67K shares of RARE (ULTRAGENYX PHARMACEUTICAL IN), valued at $5.62M, representing 3.34% of its reported portfolio and ranking #7.

Has Birchview Capital, LP been buying or selling RARE?

In the latest 13F filing (Q3 2026), Birchview Capital, LP newly opened its position in RARE. The position peaked in Q3 2026 at 373.67K shares.

Which other funds hold RARE?

Other major institutional holders of RARE include RTW INVESTMENTS, LP, FRONTIER CAPITAL MANAGEMENT CO LLC, Bellevue Group AG, among 24 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.